Indication
Influenza A (H1N1 subtype) vaccination
Influenza A (H1N1 subtype) vaccination refers to active immunization indicated for the prevention of acute respiratory disease caused by influenza A virus strains carrying the hemagglutinin 1 and neuraminidase 1 surface glycoproteins. Read more about Influenza A (H1N1 subtype) vaccination
0 drugs 0 manufacturers
Drugs that treat it
Common Influenza A (H1N1 subtype) vaccination therapies.
No drugs are available
This indication does not currently contain public drugs.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonInfluenza A (H1N1 subtype) vaccination refers to active immunization indicated for the prevention of acute respiratory disease caused by influenza A virus strains carrying the hemagglutinin 1 and neuraminidase 1 surface glycoproteins.
The target pathogen infects the human respiratory epithelium—predominantly affecting the upper and lower respiratory tracts—and frequently presents with the sudden onset of systemic and respiratory signs, including high fever, chills, myalgias, headache, nonproductive cough, and severe malaise.
In susceptible populations, such as infants, older adults, pregnant individuals, and patients with cardiopulmonary comorbidities, infection can progress to diffuse viral pneumonitis, secondary bacterial pneumonia, and acute respiratory distress syndrome.
Immunization is deployed either as a monovalent formulation or as an essential component of multivalent seasonal influenza formulations to elicit neutralizing antibodies against circulating H1N1 lineages.
- cdc.gov
Influenza A (H1N1 subtype) vaccination refers to active immunization indicated for the prevention of acute respiratory disease caused by influenza A virus strains carrying the hemagglutinin 1 and neuraminidase 1 surface glycoproteins
- fda.gov
Influenza A (H1N1 subtype) vaccination refers to active immunization indicated for the prevention of acute respiratory disease caused by influenza A virus strains carrying the hemagglutinin 1 and neuraminidase 1 surface glycoproteins Immunization is deployed either as a monovalent formulation or as an essential component of multivalent seasonal influenza formulations to elicit neutralizing antibodies against circulating H1N1 lineages
- cdc.gov
Influenza A (H1N1 subtype) vaccination refers to active immunization indicated for the prevention of acute respiratory disease caused by influenza A virus strains carrying the hemagglutinin 1 and neuraminidase 1 surface glycoproteins
- cdc.gov
The target pathogen infects the human respiratory epithelium—predominantly affecting the upper and lower respiratory tracts—and frequently presents with the sudden onset of systemic and respiratory signs, including high fever, chills, myalgias, headache, nonproductive cough, and severe malaise
- nih.gov
The target pathogen infects the human respiratory epithelium—predominantly affecting the upper and lower respiratory tracts—and frequently presents with the sudden onset of systemic and respiratory signs, including high fever, chills, myalgias, headache, nonproductive cough, and severe malaise
- cdc.gov
The target pathogen infects the human respiratory epithelium—predominantly affecting the upper and lower respiratory tracts—and frequently presents with the sudden onset of systemic and respiratory signs, including high fever, chills, myalgias, headache, nonproductive cough, and severe malaise
- cdc.gov
In susceptible populations, such as infants, older adults, pregnant individuals, and patients with cardiopulmonary comorbidities, infection can progress to diffuse viral pneumonitis, secondary bacterial pneumonia, and acute respiratory distress syndrome
- nih.gov
In susceptible populations, such as infants, older adults, pregnant individuals, and patients with cardiopulmonary comorbidities, infection can progress to diffuse viral pneumonitis, secondary bacterial pneumonia, and acute respiratory distress syndrome
- cdc.gov
Immunization is deployed either as a monovalent formulation or as an essential component of multivalent seasonal influenza formulations to elicit neutralizing antibodies against circulating H1N1 lineages
- fda.gov
Immunization is deployed either as a monovalent formulation or as an essential component of multivalent seasonal influenza formulations to elicit neutralizing antibodies against circulating H1N1 lineages
Personalize your experience
Follow Influenza A (H1N1 subtype) vaccination and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.